ARWR
Price
$38.97
Change
-$1.50 (-3.71%)
Updated
Nov 19 closing price
Capitalization
5.39B
5 days until earnings call
Intraday BUY SELL Signals
UCBJY
Price
$132.44
Change
-$0.17 (-0.13%)
Updated
Nov 19 closing price
Capitalization
50.16B
98 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARWR vs UCBJY

Header iconARWR vs UCBJY Comparison
Open Charts ARWR vs UCBJYBanner chart's image
Arrowhead Pharmaceuticals
Price$38.97
Change-$1.50 (-3.71%)
Volume$2.88M
Capitalization5.39B
UCB S.A
Price$132.44
Change-$0.17 (-0.13%)
Volume$19.52K
Capitalization50.16B
ARWR vs UCBJY Comparison Chart in %
ARWR
Daily Signal:
Gain/Loss:
UCBJY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARWR vs. UCBJY commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and UCBJY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ARWR: $38.97 vs. UCBJY: $132.44)
Brand notoriety: ARWR: Notable vs. UCBJY: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 137% vs. UCBJY: 64%
Market capitalization -- ARWR: $5.39B vs. UCBJY: $50.16B
ARWR [@Biotechnology] is valued at $5.39B. UCBJY’s [@Biotechnology] market capitalization is $50.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileUCBJY’s FA Score has 2 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • UCBJY’s FA Score: 2 green, 3 red.
According to our system of comparison, UCBJY is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 2 TA indicator(s) are bullish while UCBJY’s TA Score has 5 bullish TA indicator(s).

  • ARWR’s TA Score: 2 bullish, 6 bearish.
  • UCBJY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, UCBJY is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -5.92% price change this week, while UCBJY (@Biotechnology) price change was -0.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

ARWR is expected to report earnings on Nov 25, 2025.

UCBJY is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UCBJY($50.2B) has a higher market cap than ARWR($5.39B). ARWR YTD gains are higher at: 107.287 vs. UCBJY (35.217). UCBJY has higher annual earnings (EBITDA): 2.34B vs. ARWR (-52.51M). UCBJY has more cash in the bank: 2.01B vs. ARWR (900M). ARWR has less debt than UCBJY: ARWR (353M) vs UCBJY (2.88B). UCBJY has higher revenues than ARWR: UCBJY (6.85B) vs ARWR (573M).
ARWRUCBJYARWR / UCBJY
Capitalization5.39B50.2B11%
EBITDA-52.51M2.34B-2%
Gain YTD107.28735.217305%
P/E RatioN/A33.34-
Revenue573M6.85B8%
Total Cash900M2.01B45%
Total Debt353M2.88B12%
FUNDAMENTALS RATINGS
ARWR vs UCBJY: Fundamental Ratings
ARWR
UCBJY
OUTLOOK RATING
1..100
7114
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
10012
SMR RATING
1..100
9586
PRICE GROWTH RATING
1..100
3543
P/E GROWTH RATING
1..100
299
SEASONALITY SCORE
1..100
3950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UCBJY's Valuation (3) in the null industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.

UCBJY's Profit vs Risk Rating (12) in the null industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.

UCBJY's SMR Rating (86) in the null industry is in the same range as ARWR (95) in the Biotechnology industry. This means that UCBJY’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as UCBJY (43) in the null industry. This means that ARWR’s stock grew similarly to UCBJY’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for UCBJY (99) in the null industry. This means that ARWR’s stock grew significantly faster than UCBJY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRUCBJY
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
60%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
43%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
50%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
57%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 8 days ago
70%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 17 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
40%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signal:
Gain/Loss:
UCBJY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WYY6.270.10
+1.62%
WidePoint Corp
XOMAO25.470.07
+0.28%
XOMA Corp
CPB30.78-0.25
-0.81%
The Campbell's Company
PACK4.44-0.05
-1.11%
Ranpak Holdings Corp
LTC35.82-0.64
-1.76%
LTC Properties

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-3.71%
DNLI - ARWR
55%
Loosely correlated
-3.20%
RGNX - ARWR
52%
Loosely correlated
-2.84%
IMNM - ARWR
51%
Loosely correlated
-1.06%
IONS - ARWR
51%
Loosely correlated
-0.67%
BEAM - ARWR
50%
Loosely correlated
-4.24%
More

UCBJY and

Correlation & Price change

A.I.dvisor tells us that UCBJY and GBIO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that UCBJY and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UCBJY
1D Price
Change %
UCBJY100%
-0.13%
GBIO - UCBJY
28%
Poorly correlated
-1.14%
VANI - UCBJY
26%
Poorly correlated
-3.55%
ABOS - UCBJY
24%
Poorly correlated
-6.02%
TNYA - UCBJY
23%
Poorly correlated
-6.25%
ARWR - UCBJY
23%
Poorly correlated
-3.71%
More